ERBB2 and breast carcinoma: Despite the emergence of multiple anti‐HER2 regimens, particularly anthracycline‐free neoadjuvant or adjuvant treatments, patients with HER2‐positive breast cancer continue to confront the reality of recurrence, metastasis, or disease progression.